- Home
- LCTX vs ARCT Comparison
LCTX vs ARCT Comparison
Compare LCTX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ARCT
- Stock Information
- Founded
- LCTX 1990
- ARCT 2013
- Country
- LCTX United States
- ARCT United States
- Employees
- LCTX N/A
- ARCT N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- ARCT Health Care
- Exchange
- LCTX Nasdaq
- ARCT Nasdaq
- Market Cap
- LCTX 274.0M
- ARCT 320.8M
- IPO Year
- LCTX N/A
- ARCT N/A
- Fundamental
- Price
- LCTX $1.73
- ARCT $21.20
- Analyst Decision
- LCTX Strong Buy
- ARCT Strong Buy
- Analyst Count
- LCTX 4
- ARCT 9
- Target Price
- LCTX $4.25
- ARCT $50.88
- AVG Volume (30 Days)
- LCTX 1.9M
- ARCT 850.2K
- Earning Date
- LCTX 11-13-2025
- ARCT 11-06-2025
- Dividend Yield
- LCTX N/A
- ARCT N/A
- EPS Growth
- LCTX N/A
- ARCT N/A
- EPS
- LCTX N/A
- ARCT N/A
- Revenue
- LCTX $10,914,000.00
- ARCT $122,122,000.00
- Revenue This Year
- LCTX N/A
- ARCT N/A
- Revenue Next Year
- LCTX $176.00
- ARCT $28.92
- P/E Ratio
- LCTX N/A
- ARCT N/A
- Revenue Growth
- LCTX 76.43
- ARCT N/A
- 52 Week Low
- LCTX $0.37
- ARCT $8.04
- 52 Week High
- LCTX $1.83
- ARCT $23.85
- Technical
- Relative Strength Index (RSI)
- LCTX 69.14
- ARCT 54.94
- Support Level
- LCTX $1.64
- ARCT $20.21
- Resistance Level
- LCTX $1.77
- ARCT $23.60
- Average True Range (ATR)
- LCTX 0.11
- ARCT 1.64
- MACD
- LCTX -0.00
- ARCT -0.07
- Stochastic Oscillator
- LCTX 75.00
- ARCT 44.74
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.